To include your compound in the COVID-19 Resource Center, submit it here.

Dalbavancin: Phase III data

A retrospective reanalysis of a double-blind Phase III trial in 220 patients using the inclusion criteria defined in FDA Draft Guidance for treatment of skin infections showed that

Read the full 285 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE